Home › Astrocytoma › North Carolina › Durham
Astrocytoma clinical trials in Durham, NC
7 studies for Astrocytoma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
- Duke University Medical Center, Durham
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Duke Cancer Institute, Durham
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Duke University Health System, Durham
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Duke University Health System, Durham
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Duke University Health System, Durham
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Duke University Health System, Durham
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RecruitingPhase 1
- Duke University, Durham
Astrocytoma trials in other cities
- Houston, TX15 studies
- Boston, MA13 studies
- New York City, NY10 studies
- Chicago, IL9 studies
- Seattle, WA7 studies
- Philadelphia, PA7 studies
- Miami, FL7 studies
- San Francisco, CA6 studies
- Columbus, OH6 studies
- Aurora, CO6 studies
- Washington, DC5 studies
- Cincinnati, OH5 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)61 studies
- Non-Small Cell Lung Cancer42 studies
- Multiple Myeloma36 studies
- Acute Myeloid Leukemia34 studies
- Lung Cancer33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Colorectal Cancer30 studies
- Ovarian Cancer28 studies
- Chronic Lymphocytic Leukemia28 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.